BVS

Bioventus's stock closed at $12.69 on October 8, 2026, having gained 87.7% over the past 12 months and outperforming the S&P500 Index by 24.53% over the past six months. Key events include: on August 5, 2026, Q2 financial results showed adjusted earnings per share in line with expectations, but revenue missed estimates, leading to a premarket stock decline of approximately 6.9%, though full-year guidance was reaffirmed. On July 29, 2026, the announcement of Q2 results saw a slight stock price decrease of 0.68%. On June 2, 2026, a presentation at the Goldman Sachs conference resulted in a 2.27% stock increase. On May 6, 2026, Q1 financial results showed revenue rising 7% and beating expectations, leading to a 2.25% stock increase. On April 28, 2026, the announcement of upcoming Q1 results was followed by a 2.91% stock decrease. On March 5, 2026, the stock saw a 7.44% increase. The stock has been drifting after a strong year-to-date run, with investors weighing Q2 results, reaffirmed 2026 sales outlook, and potential new product launches against factors like reimbursement risk, debt, and product concentration.